In situ immunization leadsto tumor cell death by providing antigen-presenting cells, such as dendriticcells (DCs), with tumor antigens that result in a therapeutic anticancer immuneresponse. The market size for in situ immunization is expected to reach $34 billionby 2024, which is a large increase f.....
[更多]
Apple Rootstock GENEVA(R) 'G.16' is very precocious, similar to or better than M.9.
[更多]